Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD and NicOx sign drug agreement

MSD and NicOx sign drug agreement

22nd March 2006

MSD and NicOx have agreed a collaboration deal regarding the development of antihypertensive drugs.

The development of the drugs is dependent on the use of NicOx’s proprietary nitric oxide-donating technology and thus the company will receive an initial payment of 9.2 million euros.

Total money paid by MSD to NicOx could reach as much as 279 million euros through milestone payments.

“We are very pleased to be entering into this new collaboration with NicOx, which aims to address one of the world’s leading health problems,” said Dr Anthony Ford-Hutchinson, executive vice president of research medicine, MSD Research Laboratories.

“With this new agreement, we are building on our excellent existing relationship with NicOx to combine NicOx’s research skills with MSD’s industry-leading development and marketing capabilities in this area, with our joint goal of advancing patient care.”

The antihypertensive drugs would be used for treatment of high blood pressure, complications of hypertension and other cardiovascular and related illnesses.

MSD has said that currently, treatment to reduce high blood pressure and therefore lessen the threat posed by stroke, heart attack, heart failure and kidney failure is inadequate.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.